David J. Greenblatt

David J. Greenblatt's AcademicInfluence.com Rankings

David J. Greenblatt

Computer Science

#1588

World Rank

#1643

Historical Rank

Machine Learning

#55

World Rank

#55

Historical Rank

Database

#79

World Rank

#81

Historical Rank

Artificial Intelligence

#104

World Rank

#107

Historical Rank

computer-science Degrees

Download Badge

Computer Science

David J. Greenblatt's Degrees

PhD Computer Science Stanford University

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is David J. Greenblatt Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David J. Greenblatt's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A method for estimating the probability of adverse drug reactions (1981) (9974)
Midazolam: Pharmacology and Uses (1985) (980)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans (2010) (626)
Drug disposition in old age. (1982) (577)
Effect of Age, Gender, and Obesity on Midazolam Kinetics (1984) (558)
Effects of the Antifungal Agents on Oxidative Drug Metabolism (2000) (496)
Treatment of Postmenopausal Osteoporosis (2005) (482)
Current Status of Benzodiazepines (1983) (403)
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. (2000) (396)
Diazepam disposition determinants (1980) (363)
Drug therapy. Clinical Pharmacokinetics (first of two parts). (1975) (349)
Benzodiazepines in Clinical Practice (1974) (335)
Dose‐Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans (1997) (333)
Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models (2001) (322)
Pharmacokinetics and pharmacodynamics. (1990) (319)
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. (2001) (298)
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. (1990) (291)
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. (1981) (269)
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir (1998) (267)
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole (1999) (265)
Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. (2003) (264)
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. (2003) (263)
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates (2005) (259)
Clinical pharmacokinetics (second of two parts). (1975) (256)
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. (2003) (252)
The dexamethasone suppression test: An overview of its current status in psychiatry (1987) (247)
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. (1996) (241)
Sensitivity to triazolam in the elderly. (1991) (241)
Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents (1996) (229)
Reduced Serum Albumin Concentration in the Elderly: A Report from the Boston Collaborative Drug Surveillance Program (1979) (225)
Toxicity of high‐dose flurazepam in the elderly (1977) (224)
Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. (1978) (217)
Interaction of Warfarin With Drugs, Natural Substances, and Foods (2005) (216)
Oxazepam kinetics: effects of age and sex. (1980) (214)
Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function. (1988) (208)
Cytochrome P-450 2B6 Is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes (2001) (207)
In vitro approaches to predicting drug interactions in vivo. (1998) (205)
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. (2001) (205)
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. (2004) (204)
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. (2004) (201)
Clinical Pharmacokinetics of Oxazepam and Lorazepam (1981) (200)
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. (2000) (196)
Drug therapy. Current status of benzodiazepines. (1983) (193)
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice (2003) (186)
Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. (2000) (186)
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. (1995) (183)
Saint John's wort: An in vitro analysis of P‐glycoprotein induction due to extended exposure (2001) (183)
Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. (1990) (181)
Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. (2002) (180)
Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. (2000) (180)
Benzodiazepines: a summary of pharmacokinetic properties. (1981) (174)
The effect of grapefruit juice on drug disposition (2011) (174)
Postexercise peril. Plasma catecholamines and exercise. (1984) (171)
Drug Disposition in Obese Humans (1986) (171)
Effect of age and gender on disposition of temazepam. (1981) (170)
Use of benzodiazepines in anxiety disorders. (1993) (170)
Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. (1973) (168)
Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. (1994) (168)
Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly (1991) (167)
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. (1973) (167)
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. (1994) (166)
Kinetics of intravenous and intramuscular morphine (1978) (166)
Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. (1986) (165)
O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants (1999) (162)
Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly (2012) (160)
Drug interactions with newer antidepressants: role of human cytochromes P450. (1998) (160)
Reduced benzodiazepine sensitivity in panic disorder. (1990) (157)
Drug metabolism and drug interactions: application and clinical value of in vitro models. (2003) (157)
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial (2014) (156)
Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. (1980) (154)
Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 (1998) (154)
Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. (1997) (152)
Variability of 24‐Hour Urinary Creatinine Excretion by Normal Subjects (1976) (152)
Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans (1979) (152)
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. (1983) (150)
Lorazepam kinetics in the elderly (1979) (150)
Inhibition of human cytochromes P450 by components of Ginkgo biloba (2004) (148)
Differential Modulation of P-Glycoprotein Expression and Activity by Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors in Cell Culture (2002) (148)
Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo (1989) (146)
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. (1980) (145)
Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. (1984) (145)
Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs (1981) (143)
Clinical Pharmacokinetics of Alprazolam (1993) (143)
Intramuscular injection of drugs. (1976) (143)
The Pharmacokinetics of Midazolam in Chronic Renal Failure Patients (1983) (142)
Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. (1974) (138)
Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo (2005) (137)
Fluoxetine impairs clearance of alprazolam but not of clonazepam (1992) (135)
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. (1999) (134)
ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO (2005) (134)
In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. (2000) (134)
Imipramine and desipramine disposition in the elderly. (1985) (133)
Pharmacokinetics of Drugs in Obesity (1982) (133)
Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. (2001) (131)
Alterations in drug distribution and clearance due to obesity. (1981) (131)
Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations (1982) (130)
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. (2001) (129)
Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. (1982) (128)
Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. (1977) (127)
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. (1978) (127)
Biotransformation of Chlorzoxazone by Heptatic Microsomes from Humans and Ten Other Mammalian Species (1997) (126)
Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. (1991) (125)
Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. (2000) (124)
Obesity, sex, and acetaminophen disposition (1982) (123)
Diazepam kinetics in relation to age and sex. (1981) (123)
Benzodiazepine sensitivity in normal human subjects. (1986) (122)
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors (2001) (122)
Clinical Pharmacokinetics of the Newer Benzodiazepines (1983) (121)
Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences (1998) (121)
Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. (1997) (121)
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. (2000) (120)
Concentration‐independent plasma protein binding of benzodiazepines (1983) (118)
Trazodone kinetics: Effect of age, gender, and obesity (1987) (118)
Alprazolam‐ritonavir interaction: Implications for product labeling (2000) (118)
Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice (1987) (118)
Evaluation of digoxin bioavailability in single-dose studies. (1973) (117)
Acute overdosage with benzodiazepine derivatives (1977) (117)
Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. (2003) (115)
Zolpidem for insomnia (2012) (114)
In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction (1994) (114)
Metabolism of Drugs by Cytochrome P450 3A Isoforms (1995) (114)
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo (1998) (112)
Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. (1983) (112)
UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver (2004) (111)
Clinical Pharmacokinetics of Quinidine (1980) (110)
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine (1996) (110)
A controlled trial of amantadine in drug-induced extrapyramidal disorders. (1976) (110)
Daytime carryover of triazolam and flurazepam in elderly insomniacs. (1982) (109)
Alprazolam kinetics in the elderly. Relation to antipyrine disposition. (1983) (109)
UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S) (2005) (107)
Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. (1982) (107)
Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. (2001) (103)
The Effects of a Benzodiazepine Antagonist Ro 15–1788 in the Presence of Stable Concentrations of Midazolam (1985) (103)
Absorption and Disposition of Chlordiazepoxide in Young and Elderly Male Volunteers (1977) (103)
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat (2002) (103)
Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. (1983) (103)
Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. (1993) (103)
Drug therapy. Benzodiazepines (first of two parts). (1974) (103)
Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A (1998) (101)
Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. (1989) (99)
Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines (1989) (98)
Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration (1986) (98)
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine (2001) (98)
Automated gas chromatography for studies of midazolam pharmacokinetics. (1981) (97)
Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. (1983) (97)
Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (2013) (97)
Absolute Bioavailability of Oral and Intramuscular Diazepam: Effects of Age and Sex (1983) (96)
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies (2006) (96)
Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. (1987) (96)
N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. (1995) (95)
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. (2003) (95)
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. (2003) (95)
Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. (1984) (94)
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. (2011) (93)
Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs (1999) (93)
Clinical Importance of the Interaction of Diazepam and Cimetidine (1984) (93)
Fexofenadine Transport in Caco‐2 Cells: Inhibition with Verapamil and Ritonavir (2002) (93)
Elimination half-life of drugs: value and limitations. (1985) (93)
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. (1999) (93)
Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences (1998) (93)
Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines (1996) (93)
Kinetics of intravenous and intramuscular morphine. (1979) (93)
Clinical pharmacokinetics of lorazepam (1976) (92)
Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir (2000) (92)
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole (2000) (92)
On the psychopharmacology of beta adrenergic blockade. (1972) (92)
Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. (1987) (91)
Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. (1983) (91)
Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. (1981) (91)
Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time (1992) (90)
Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat (1984) (90)
Clinical use and toxicity of intravenous lidocaine (1976) (90)
High-performance liquid chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. (1981) (89)
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. (1983) (89)
The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam (1984) (89)
Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. (1979) (89)
Digoxin disposition in obesity: clinical pharmacokinetic investigation. (1981) (89)
Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. (1981) (88)
Acetaminophen kinetics in the elderly (1982) (88)
Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs (2008) (87)
Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences (2000) (87)
Desmethyldiazepam kinetics in the elderly after oral prazepam (1980) (87)
Increased sensitivity of the elderly to the central depressant effects of diazepam. (1985) (87)
Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. (1985) (86)
Rapid Assessment of P-Glycoprotein Inhibition and Induction in Vitro (2003) (85)
Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice (2007) (85)
Reduced quinidine clearance in elderly persons. (1978) (85)
Metabolism of Dextromethorphan in vitro: Involvement of Cytochromes P450 2D6 AND 3A3/4, with a Possible Role of 2E1 (1997) (85)
Impairment of Antipyrine Clearance in Humans by Propranolol (1978) (84)
Bioavailability of Drugs: The Digoxin Dilemma (1976) (84)
Rapid recovery from massive diazepam overdose. (1978) (84)
Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects (1999) (84)
Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon (2003) (84)
Chronic benzodiazepine administration. II. Discontinuation syndrome is associated with upregulation of gamma-aminobutyric acidA receptor complex binding and function. (1988) (84)
Intramuscular injection-site complications. (1978) (84)
Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam (1982) (84)
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (2005) (84)
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. (1996) (83)
Psychotropic drug use in the Boston area. A report from the Boston Collaborative Drug Surveillance Program. (1975) (83)
Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. (1998) (83)
Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects (2012) (82)
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. (2000) (82)
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. (2002) (82)
Diazepam absorption: Effect of antacids and food (1978) (82)
Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. (1993) (81)
Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers (2007) (81)
Mechanism of cytochrome P450‐3A inhibition by ketoconazole (2011) (81)
Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. (1981) (80)
Midazolam Pharmacodynamics and Pharmacokinetics during Acute Hypovolemia (1985) (80)
Phenelzine and the dream machine--ramblings and reflections. (1985) (80)
THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER (2006) (80)
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (2004) (80)
Impairment of lidocaine clearance in elderly male subjects. (1983) (80)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir (2006) (80)
Plasma protein binding of drugs after severe burn injury (1984) (79)
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions (1999) (79)
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration (2014) (79)
Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. (1989) (79)
Pharmacology of benzodiazepine hypnotics. (1992) (78)
Human cytochromes mediating N-demethylation of fluoxetine in vitro (1997) (78)
Clobazam kinetics in the elderly. (1981) (77)
Lidocaine disposition in obesity. (1984) (77)
Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats (2004) (76)
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? (1986) (76)
Prolonged Accumulation of Diazepam in Obesity (1983) (76)
Phenytoin disposition in obesity. Determination of loading dose. (1985) (76)
Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. (1998) (76)
Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. (1988) (75)
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. (2000) (75)
Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. (1983) (74)
Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. (1977) (73)
Effects of three antibiotics on theophylline kinetics (1979) (73)
Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. (2000) (73)
The UDP-Glucuronosyltransferase (UGT) 1A Polymorphism c.2042C>G (rs8330) Is Associated with Increased Human Liver Acetaminophen Glucuronidation, Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio, and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure (2013) (73)
Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. (1992) (72)
Clinical pharmacokinetics of lorazepam: a review. (1978) (71)
Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers (2013) (71)
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. (1980) (70)
Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide (1978) (70)
Diazepam interaction with antituberculosis drugs (1981) (70)
Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome (1999) (69)
Analysis of lorazepam and its glucoronide metabolite by electron-capture gas—liquid chromatography (1978) (69)
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. (2015) (69)
Comparative single‐dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo (1988) (69)
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (1998) (68)
Drug therapy. Anticholinergics. (1973) (68)
Clinical implications of benzodiazepine pharmacokinetics. (1977) (68)
Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. (1998) (68)
Absolute and relative bioavailability of oral acetaminophen preparations. (1983) (67)
The B lymphocyte calcium response to anti-Ig is diminished by membrane immunoglobulin cross-linkage to the Fc gamma receptor. (1987) (67)
Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. (2003) (67)
Imipramine disposition in users of oral contraceptive steroids (1984) (67)
Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. (1983) (66)
Pharmacokinetic and clinical implications of quinidine protein binding. (1979) (66)
Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity (2005) (65)
Crosslinkage of B lymphocyte surface immunoglobulin by anti-Ig or antigen induces prolonged oscillation of intracellular ionized calcium (1987) (65)
Pharmacokinetic and Pharmacodynamic Interactions Between Zolpidem and Caffeine (2007) (65)
A randomized trial of mexiletine in ALS (2016) (64)
Absorption and disposition of ibuprofen in the elderly. (1984) (64)
Glycoconjugates as noninvasive probes of intrahepatic metabolism: pathways of glucose entry into compartmentalized hepatic UDP-glucose pools during glycogen accumulation. (1986) (63)
Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. (1999) (63)
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies (2001) (62)
Role of CYP3A and CYP2E1 in Alcohol-Mediated Increases in Acetaminophen Hepatotoxicity: Comparison of Wild-Type and Cyp2e1(–/–) Mice (2007) (62)
Clinical Pharmacokinetics of Chlordiazepoxide (1975) (62)
Drug therapy: drug disposition in old age. (1982) (61)
Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450‐2C9 Substrate (2006) (61)
Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone (2003) (61)
Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney (2004) (61)
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. (2009) (61)
Effect of Food on Acetaminophen Absorption in Young and Elderly Subjects (1982) (61)
Pharmacokinetics of antipyrine, acetaminophen and lidocaine in fed and fasted horses. (1987) (60)
Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. (1999) (60)
Drug interactions with grapefruit juice: an update. (2001) (60)
Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose‐Escalation Trials (2006) (60)
Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. (1996) (60)
Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses (1975) (60)
Clinical toxocity of theophylline in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program. (1978) (59)
Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. (1993) (59)
Liver injury associated with ketoconazole: Review of the published evidence (2014) (59)
Flow cytometric analysis of murine splenic B lymphocyte cytosolic free calcium response to anti-IgM and anti-IgD. (1987) (59)
Chlordiazepoxide and oxazepam disposition in cirrhosis (1979) (59)
Technique for external beam treatment for mesothelioma. (1987) (59)
Analysis of Drug Interactions Involving Fruit Beverages and Organic Anion‐Transporting Polypeptides (2009) (59)
Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study. (1989) (59)
Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. (1978) (58)
Benzodiazepine receptors mediate regional blood flow changes in the living human brain. (1995) (58)
Pharmacokinetic approach to the clinical use of lidocaine intravenously. (1976) (58)
Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. (1989) (58)
Simultaneous gas-chromatographic analysis for diazepam and its major metabolite, desmethyldiazepam, with use of double internal standardization. (1978) (57)
Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2 (2007) (57)
Inhibition of Human Cytochrome P450‐3A Isoforms by Fluoxetine and Norfluoxetine: In Vitro and In Vivo Studies (1996) (56)
Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation (1983) (56)
Pharmacokinetics in clinical practice (1985) (56)
Balancing efficacy and safety in the use of oral sedation in dental outpatients. (2006) (56)
Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. (1989) (56)
Kinetics of high‐dose intravenous morphine in cardiac surgery patients (1976) (56)
Dynamics and Kinetics of a Modified‐Release Formulation of Zolpidem: Comparison With Immediate‐Release Standard Zolpidem and Placebo (2006) (56)
Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. (1983) (56)
Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: Kinetic‐dynamic studies (1994) (55)
Population study of triazolam pharmacokinetics. (1986) (55)
Age Does Not Alter Acetaminophen Absorption (1982) (55)
Adverse Reactions to Spironolactone (1973) (55)
FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES (2006) (54)
Ibuprofen disposition in obese individuals. (1985) (54)
Triazolam and anterograde amnesia: all is not well in the Z-zone. (1983) (54)
Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption (1976) (54)
Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol (1987) (54)
Impairment of antipyrine metabolism by low‐dose oral contraceptive steroids (1981) (54)
Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. (2004) (53)
UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5′-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation (2005) (53)
Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. (1984) (53)
Pharmacokinetics of Efavirenz When Co‐administered With Rifampin in TB/HIV Co‐infected Patients: Pharmacogenetic Effect of CYP2B6 Variation (2008) (53)
Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. (1996) (53)
Serotonin (5-hydroxytryptamine) glucuronidation in vitro : assay development, human liver microsome activities and species differences (2003) (53)
Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). (1982) (53)
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. (2001) (53)
The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. (1986) (52)
Pharmacokinetic aspects of drug therapy in the elderly. (1986) (52)
Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder (2005) (52)
Lorazepam and oxazepam kinetics in women on low‐dose oral contraceptives (1983) (52)
Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. (1990) (52)
Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. (1996) (52)
Population Pharmacokinetics of Methylphenidate in Children with Attention‐Deficit Hyperactivity Disorder (1999) (52)
Pharmacokinetics and Clinical Effects of Alprazolam Following Single and Multiple Oral Doses in Patients With Panic Disorder (1986) (51)
From Disordered Eating to Addiction: The “Food Drug” in Bulimia Nervosa (2012) (51)
Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. (1989) (51)
Midazolam pharmacology and pharmacokinetics (1985) (51)
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors (2000) (51)
A Large‐Sample Study of Diazepam Pharmacokinetics (1989) (51)
Clonazepam pharmacokinetics, brain uptake, and receptor interactions. (1987) (51)
Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques (2002) (50)
Adverse reactions to intravenous diazepam:: A report from the Boston Collaborative Drug Surveillance Program (1973) (50)
Clorazepate and lorazepam: clinical improvement and rebound anxiety. (1988) (50)
Clinical pharmacokinetics of lorazepam; II. Intramuscular injection (1977) (49)
Prazepam and lorazepam, two new benzodiazepines. (1978) (49)
Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man (1998) (49)
Influence of serum digoxin concentration measurements on frequency of digitoxicity (1974) (49)
Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. (2000) (48)
Kinetics of intravenous chlordiazepoxide: Sex differences in drug distribution (1977) (48)
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. (2005) (48)
Biochemical Basis for Deficient Paracetamol Glucuronidation in Cats: an Interspecies Comparison of Enzyme Constraint in Liver Microsomes (1997) (48)
The clinician and drug interactions--an update. (1996) (48)
The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Double‐Blind Trial (2009) (48)
Gynecomastia and impotence: complications of spironolactone therapy. (1973) (48)
Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. (2000) (48)
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. (1993) (48)
Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. (1989) (48)
Enhanced Bioavailability of Triazolam Following Sublingual Versus Oral Administration (1986) (48)
Induction of P‐glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells (2007) (48)
Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. (2003) (47)
Simple and rapid liquid chromatography method for determination of efavirenz in plasma. (2006) (47)
Drug effects in hospitalized patients : experiences of the Boston Collaborative Drug Surveillance Program, 1966-1975 (1976) (47)
Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure (2014) (47)
Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. (2001) (47)
Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly Volunteers (1998) (46)
The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and self-rated sedation. (1998) (46)
Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. (1981) (46)
Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns (2007) (46)
Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. (1985) (46)
Increased Metabolic Clearance of Acetaminophen with Oral Contraceptive Use (1982) (46)
In vitro interactions of water-soluble garlic components with human cytochromes p450. (2006) (45)
Interaction of propoxyphene with diazepam, alprazolam and lorazepam. (1985) (45)
'GABA shift' in vivo: enhancement of benzodiazepine binding in vivo by modulation of endogenous GABA. (1988) (45)
Clobazam Kinetics: Intrasubject Variability and Effect of Food on Absorption (1982) (45)
Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. (1992) (45)
Alprazolam is another substrate for human cytochrome P450-3A isoforms. (1998) (45)
Appropriate Use and Regulatory Control of Benzodiazepines (1991) (45)
Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies (2008) (45)
Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. (2004) (44)
Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal. (1978) (44)
Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. (1990) (44)
Personality and benzodiazepine sensitivity in anxious patients and control subjects (1993) (43)
Sedative effects and impaired learning and recall after single oral doses of lorazepam (1986) (43)
Benzodiazepine hypnotics: kinetic and therapeutic options. (1982) (43)
Chronic benzodiazepine administration (1991) (43)
Long-term administration of benzodiazepines: pharmacokinetic versus pharmacodynamic tolerance. (1986) (43)
Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. (2003) (43)
Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement (1988) (43)
The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. (2006) (43)
Uses and toxicity of belladonna alkaloids and synthetic anticholinergics. (1971) (43)
Methadone inhibits rhodamine123 transport in Caco-2 cells. (2001) (43)
Slow absorption of intramuscular chlordiazepoxide. (1974) (43)
Eye movement effects of diazepam in sons of alcoholic fathers and male control subjects. (1994) (43)
Oxaprozin pharmacokinetics in the elderly. (1985) (43)
Cytochromes in psychopharmacology. (1994) (43)
Flurazepam hydrochloride, a benzodiazepine hypnotic. (1975) (43)
Interaction of disulfiram with benzodiazepines (1978) (42)
ROLE OF THE NUCLEAR RECEPTOR PREGNANE X RECEPTOR IN ACETAMINOPHEN HEPATOTOXICITY (2005) (42)
Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment (1995) (42)
Clinical Pharmacokinetics of the Benzodiazepines (1985) (42)
Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers (2017) (42)
Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam (2005) (42)
Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. (1983) (42)
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. (2009) (42)
The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma (1986) (42)
Bioavailability of digoxin tablets and elixir in the fasting and postprandial states (1974) (41)
Dose-independent pharmacokinetics of digoxin in humans. (1978) (41)
Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. (1986) (41)
Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. (1983) (41)
A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis (2010) (41)
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. (2011) (40)
Kinetics and dynamics of lorazepam during and after continuous intravenous infusion (2000) (40)
Massive benzodiazepine requirements during acute alcohol withdrawal. (1979) (40)
Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. (1999) (40)
Six Weeks of Diazepam Treatment in Normal Women: Effects on Psychomotor Performance and Psychophysiology (1988) (40)
The Neuropsychiatric Effects of Aspartame in Normal Volunteers (1990) (39)
Cimetidine Impairs Clearance of Antipyrine and Desmethyldiazepam in the Elderly (1982) (39)
Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. (1984) (39)
Drug therapy. Benzodiazepines (second of two parts). (1974) (39)
Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. (1986) (39)
Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam (1988) (39)
Cognitive effects of β‐adrenergic antagonists after single doses: Pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo (1993) (39)
Intravenous digoxin as a bioavailability standard: Slow infusion and rapid injection (1974) (38)
Bees, ginseng and MAOIs revisited. (1988) (38)
The Effect of Age on P-Glycoprotein Expression and Function in the Fischer-344 Rat (2004) (38)
Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes (2009) (38)
Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: Relation to lipid solubility (1985) (38)
Factors influencing diazepam pharmacokinetics: age, sex, and liver disease. (1978) (38)
Benzodiazepine hypnotics: sorting the pharmacokinetic facts. (1991) (38)
Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone (1992) (38)
Effects of age and other drugs on benzodiazepine kinetics. (1980) (38)
Serum haloperidol concentrations and clinical response in acute psychosis. (1984) (38)
Human cytochromes mediating sertraline biotransformation: seeking attribution. (1999) (38)
Automated gas chromatographic determination of plasma alprazolam concentrations. (1983) (38)
Fluoxetine inhibition of phenytoin metabolism. (1994) (37)
Ritonavir Has Minimal Impact on the Pharmacokinetic Disposition of a Single Dose of Bupropion Administered to Human Volunteers (2006) (37)
Neuroendocrine effects of diazepam in panic and generalized anxiety disorders (1991) (37)
Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (1985) (37)
Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam (1988) (37)
Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. (1976) (37)
Rational therapeutic drug monitoring. (1986) (36)
Psychotropic drug prescribing in the United States: extent, costs, and expenditures. (2011) (36)
Benzodiazepine Receptor Binding of Triazolobenzodiazepines In Vivo: Increased Receptor Number with Low‐Dose Alprazolam (1987) (36)
Metabolism of haloperidol: clinical implications and unanswered questions. (1994) (36)
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. (1991) (36)
Pharmacokinetic Understanding of Antianxiety Drug Therapy (1978) (36)
Oral Contraceptives and Hypertension: A Report From the Boston Collaborative Drug Surveillance Program (1974) (36)
Preliminary evidence of benzodiazepine subsensitivity in panic disorder (1989) (36)
Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. (2004) (35)
Management of anxiety in the elderly: the balance between therapeutic and adverse effects. (1982) (35)
Pharmacokinetics of alprazolam. (1983) (35)
Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. (1999) (35)
Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. (1978) (35)
Pharmacokinetics and Clinical Effects of Amantadine in Drug‐Induced Extrapyramidal Symptoms (1977) (35)
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. (2013) (35)
Physiologic Changes in Old Age: Relation to Altered Drug Disposition (1982) (35)
Clinical Pharmacokinetics of Antidepressants in the Elderly (1993) (35)
Meprobamate overdosage: a continuing problem. (1977) (35)
Effect of age and sex on lorazepam protein binding (1982) (35)
Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome P‐450 2C9 and Metabolic Inhibitors (1997) (35)
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection (2018) (35)
Kinetic equivalence of stable‐isotope‐labeled and unlabeled phenytoin (1981) (34)
The Relationship of Alprazolam Dose to Steady‐State Plasma Concentrations (1990) (34)
Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program. (1976) (34)
P‐glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture (2001) (34)
Increased cimetidine clearance in burn patients. (1985) (34)
Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in‐vitro inhibition studies (2017) (34)
Apparent mechanism‐based inhibition of human CYP3A in‐vitro by lopinavir (2003) (34)
Altered Drug Disposition Following Bariatric Surgery: A Research Challenge (2015) (34)
Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance (1988) (34)
Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results (1977) (34)
Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. (1993) (34)
Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. (1998) (34)
Basic pharmacokinetic principles and their application to psychotropic drugs. (1993) (34)
Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat (2017) (34)
Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism (2010) (34)
Response to diazepam in sons of alcoholics. (1992) (34)
Interaction of ibuprofen with the H‐2 receptor antagonists ranitidine and cimetidine (1985) (34)
Clinical toxicity of furosemide in hospitalized patients (1977) (34)
Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies. (1997) (34)
Trimipramine kinetics and absolute bioavailability: Use of gas‐liquid chromatography with nitrogen‐phosphorus detection (1984) (34)
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis (2008) (34)
Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P‐glycoprotein (2002) (34)
Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes (2004) (33)
Apolipoprotein E ε4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults. (2005) (33)
Chronic benzodiazepine administration. VI. A partial agonist produces behavioral effects without tolerance or receptor alterations. (1990) (33)
Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABAA‐receptor function (1990) (33)
Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro (2010) (33)
Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. (1984) (33)
Kinetics and Dynamics of Intravenous Adinazolam, N‐Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers (2005) (33)
Evidence for regulation of UDP‐glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers (2013) (33)
Triazolam and ethanol interaction: Kinetic and dynamic consequences (1985) (33)
Induction of antigen-specific proliferation in affinity-purified small B lymphocytes: requirement for BSF-1 by type 2 but not type 1 thymus-independent antigens. (1986) (33)
Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. (1989) (33)
Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome (1995) (32)
The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. (1997) (32)
Interaction of Diazepam With Famotidine and Cimetidine, Two H2‐Receptor Antagonists (1986) (32)
A controlled trial of diazepam withdrawal in chronically anxious outpatients (1982) (32)
Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. (2005) (32)
Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. (1987) (32)
Reduced Single-dose Clearance of Clobazam in Elderly Men Predicts Increased Multiple-dose Accumulation (1983) (32)
Meprobamate: a study of irrational drug use. (1971) (32)
Cytokine modulation of chondrocyte proteinase release. (1984) (32)
Benzodiazepine discontinuation syndromes. (1990) (31)
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. (1984) (31)
In vitro‐in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude (2004) (31)
Benzodiazepine pharmacodynamics: utility of eye movement measures (2005) (31)
Single‐Dose Pharmacokinetics and Pharmacodynamics of Alprazolam in Elderly and Young Subjects (1998) (31)
Oxidative versus conjugative biotransformation of temazepam. (1990) (31)
Pharmacokinetics of Benzodiazepines and Psychostimulants in Children (1983) (31)
Clinical toxicity of chloridazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston collaborative drug surveillance Program (1974) (30)
Zolpidem and Gender: Are Women Really At Risk? (2019) (30)
Suppression of norepinephrine appearance rate in plasma by diazepam in humans. (1988) (30)
Pharmacokinetics of d‐Tubocurarine in Patients with Thermal Injury (1982) (30)
Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. (1997) (30)
Lorazepam conjugation is unimpaired in burn trauma (1988) (30)
Absence of Interaction of Cimetidine and Ranitidine with Intravenous and Oral Midazolam (1986) (30)
Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital (2003) (30)
Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. (2008) (30)
A simplex procedure for fitting nonlinear pharmacokinetic models. (1987) (30)
Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. (1981) (30)
Serotonin in Affective Disorders: Anatomic, Pharmacologic, and Clinical Perspectives, a Symposium (1987) (30)
The archaic barbiturate hypnotics. (1974) (30)
Diazepam Kinetics in Patients with Severe Burns (1983) (30)
Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans. (1978) (29)
Increased clearance of digoxin in rabbits during repeated administration. (1978) (29)
Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid (1993) (29)
Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin (2003) (29)
Update on Psychotropic Drug Prescribing in the United States: 2014-2015. (2017) (29)
Entry of quinidine into cerebrospinal fluid. (1980) (29)
Alprazolam Pharmacokinetics in Women on Low‐Dose Oral Contraceptives (1988) (29)
The Clinical Choice of Sedative-Hypnotics (1972) (28)
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms (1997) (28)
Low-dose alprazolam augments motor activity in mice (1988) (28)
Antipyrine absorption and disposition in the elderly. (1988) (28)
Pomegranate Juice and Pomegranate Extract Do Not Impair Oral Clearance of Flurbiprofen in Human Volunteers: Divergence From In Vitro Results (2012) (28)
Chronic administration of benzodiazepines—V. Rapid onset of behavioral and neurochemical alterations after discontinuation of alprazolam (1990) (28)
Defining the Maximum Tolerated Dose: Investigator, Academic, Industry and Regulatory Perspectives (1997) (28)
Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. (2000) (28)
Studies With Stable Isotopes II: Phenobarbital Pharmacokinetics During Monotherapy (1985) (27)
Temazepam clearance unaltered in cirrhosis. (1986) (27)
Glycoconjugates as noninvasive probes of intrahepatic metabolism: I. Kinetics of label incorporation with evidence of a common precursor UDP-glucose pool for secreted glycoconjugates. (1987) (27)
Pharmacokinetic Equivalence of Stable—Isotope‐Labeled and Unlabeled Drugs. Phenobarbital in Man (1982) (27)
Impairment of Digoxin Clearance by Coadministration of Quinidine (1981) (27)
Clinical pharmacology and the aged patient (1981) (27)
Propranolol interactions with diazepam, lorazepam, and alprazolam (1984) (27)
Cimetidine impairs nitrazepam clearance (1983) (27)
Pharmacokinetic properties of benzodiazepine hypnotics. (1983) (27)
Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. (1978) (27)
A clinical study of flurazepam. (1982) (27)
Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia (2016) (27)
Reactions to ethanol and diazepam in healthy young men. (1991) (27)
Interactions of tamoxifen, N‐desmethyltamoxifen and 4‐hydroxytamoxifen with P‐glycoprotein and CYP3A (2004) (26)
Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. (1998) (26)
Equivalent bioavailability from digoxin elixir and rapid-dissolution tablets. (1974) (26)
Clinical Studies of Drug–Drug Interactions: Design and Interpretation (2010) (26)
Liability to alprazolam abuse in daughters of alcoholics. (1996) (26)
Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly (2008) (26)
Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. (1988) (26)
Pharmacokinetics of benzodiazepine hypnotics. (1982) (26)
Pharmacokinetics in clinical medicine: oxazepam versus other benzodiazepines. (1975) (26)
Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers (2011) (26)
Pharmacodynamic and receptor binding changes during chronic lorazepam administration (2001) (26)
Gabapentin and Pregabalin for the Treatment of Anxiety Disorders (2018) (26)
The Pharmacokinetics of Doxylamine: Use of Automated Gas Chromatography With Nitrogen‐Phosphorus Detection (1985) (26)
Entry of diazepam and its major metabolite into cerebrospinal fluid (2004) (26)
Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. (1984) (26)
Prenatal exposure to benzodiazepine—I. Prenatal exposure to lorazepam in mice alters open-field activity and GABAA receptor function (1991) (26)
International Task Force on Benzodiazepines (2018) (26)
Alterations in Pharmacodynamics of Anxiolytics in Abstinent Alcoholic Men: Subjective Responses, Abuse Liability, and Electroencephalographic Effects of Alprazolam, Diazepam, and Buspirone (1997) (25)
Alprazolam Kinetics Following Sublingual and Oral Administration (1987) (25)
Treatment of diazepam withdrawal syndrome with propranolol. (1981) (25)
Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue. A comparison with plasma concentrations in the rat. (1983) (25)
Caffeine‐induced behavioural stimulation is dose‐ and concentration‐dependent (1990) (25)
Single‐ and multiple‐dose kinetics of intravenous digoxin (1980) (25)
Kinetics and EEG Effects of Midazolam during and after 1‐Minute, 1‐Hour, and 3‐Hour Intravenous Infusions (2004) (25)
Methsuxirnide for complex partial seizures (1983) (25)
Benzodiazepine receptor binding: Influence of physiologic and pharmacologic factors (1987) (25)
Chronic benzodiazepine administration. III. Upregulation of gamma-aminobutyric acidA receptor binding and function associated with chronic benzodiazepine antagonist administration. (1989) (25)
Clinical toxicity of reserpine in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program (1976) (24)
Interaction of triazolam and ketoconazole (1995) (24)
Doxylamine and Diphenhydramine Pharmacokinetics in Women on Low‐Dose Estrogen Oral Contraceptives (1989) (24)
Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen (2015) (24)
Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. (1990) (24)
Determination of desmethyldiazepam in plasma by electron-capture GLC: application to pharmacokinetic studies of clorazepate. (1978) (24)
Evidence‐based choice of ritonavir as index CYP3A inhibitor in drug‐drug interaction studies (2016) (24)
Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate (1979) (24)
Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. (2005) (24)
Inhibition of Triazolam Hydroxylation by Ketoconazole, Itraconazole, Hydroxyitraconazole and Fluconazole In‐vitro (1998) (24)
Alcohol does not enhance diazepam absorption. (1981) (23)
Age-related changes in the pharmacokinetic disposition of diazepam in foals. (1997) (23)
Diphenhydramine determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single low-dose pharmacokinetic studies. (1983) (23)
Tissue Distribution of Diazepam and Its Metabolite Desmethyldiazepam: A Human Autopsy Study (1985) (23)
Modification of γ‐Aminobutyric AcidA Receptor Binding and Function by N‐Ethoxycarbonyl‐2‐Ethoxy‐1,2‐Dihydroquinoline In Vitro and In Vivo: Effects of Aging (1991) (23)
In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. (2002) (23)
Cimetidine disposition in obesity. (1984) (23)
Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination (1988) (23)
Is Volume of Distribution at Steady State a Meaningful Kinetic Variable? (1983) (23)
Mechanisms and Consequences of Drug‐Drug Interactions (2017) (23)
Effect of food on enteral absorption of quinidine (1980) (23)
Noninteraction of temazepam and cimetidine. (1984) (23)
The Pharmacovigilance Syndrome. (2015) (23)
Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast (1999) (23)
Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipyrine, diazepam, and lorazepam (1984) (23)
Kinetic and dynamic interaction of brotizolam and ethanol. (1986) (23)
Effect of beta blockade on plasma catecholamine levels during psychological and exercise stress. (1984) (23)
Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity (2006) (23)
Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors (2015) (23)
Chronic Treatment with Fluvoxamine, Clovoxamine, and Placebo: Interaction with Digoxin and Effects on Sleep and Alertness (1989) (23)
The use of benzodiazepines in clinical practice. (1981) (22)
Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. (1996) (22)
Interaction of Cimetidine with Oxazepam, Lorazepam, and Flurazepam (1984) (22)
Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6 (2014) (22)
Validity of Self‐Reports of Caffeine Use (1991) (22)
Lorazepam discontinuation promotes ‘inverse agonist’ effects of benzodiazepines (1989) (22)
Newer antidepressants: hypotheses and evidence. (1997) (22)
Chronic benzodiazepine administration (2005) (22)
Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: application to single-dose pharmacokinetic studies. (1981) (22)
Predicting steady state serum concentrations of drugs. (1979) (22)
Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. (1984) (22)
Adverse reactions to intravenous diazepam (Valium): a report from the Boston Collaborative Drug Surveillance Program (1976) (22)
Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. (1990) (21)
Clinical Pharmacology and Therapeutics of Antidepressants (2004) (21)
Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects (1998) (21)
CLINICAL TOXICITY OF CHLORDIAZEPOXIDE AND DIAZEPAM IN RELATION TO SERUM ALBUMIN CONCENTRATION: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM (1975) (21)
Effect of Magnesium—Aluminum Hydroxide and Kaolin—Pectin on Absorption of Digoxin from Tablets and Capsules (1981) (21)
Phenobarbital does not alter phenytoin steady‐state serum concentration or pharmacokinetics (1988) (21)
Hypnotic effects of low doses of quazepam in older insomniacs. (1997) (21)
Noninteraction of digitoxin and quinidine. (1980) (21)
Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. (1980) (21)
Zolpidem Pharmacokinetic Properties in Young Females: Influence of Smoking and Oral Contraceptive Use (2002) (21)
Which drug for alcohol withdrawal? (1972) (21)
Studies With Stable Isotopes I: Changes in Phenytoin Pharmacokinetics and Biotransformation During Monotherapy (1985) (21)
Hyperforin Plasma Level as a Marker of Treatment Adherence in the National Institutes of Health Hypericum Depression Trial (2005) (20)
Determination of albuterol in human plasma by high-performance liquid chromatography with fluorescence detection. (1986) (20)
Drug abuse and the emergency room physician. (1974) (20)
Lack of influence of cigarette smoking on triazolam pharmacokinetics. (1987) (20)
Differential modulation of benzodiazepine receptor binding by ethanol in LS and SS mice (1988) (20)
Handbook of drug therapy (1979) (20)
Multiple complications and death following protriptyline overdose. (1974) (20)
Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses (2006) (20)
Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia (2004) (20)
Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. (1984) (20)
Benzodiazepine receptor binding of benzodiazepine hypnotics: Receptor and ligand specificity (1992) (20)
Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers (2004) (20)
A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. (2000) (20)
Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. (1983) (19)
Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes (2017) (19)
Cytochrome P-450 2 B 6 Is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes (2000) (19)
Clinical Effects of Chloral Hydrate in Hospitalized Medical Patients. (1979) (19)
Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. (2003) (19)
Clozapine and fluvoxamine, a curious complexity. (1998) (19)
Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications (2012) (19)
Clearance of the Antihistamine Doxylamine (1989) (19)
Benzodiazepine drug-drug interactions commonly occurring in clinical practice. (1984) (19)
The behavioural effects of lorazepam are poorly related to its concentration in the brain. (1983) (19)
The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state (1992) (19)
Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. (1984) (19)
Characterization of cognitive dysfunction in Sjögren’s syndrome patients (2014) (19)
Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans☆ (1980) (19)
Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. (1998) (19)
Potassium, antipsychotic agents, arrhythmias, and sudden death. (1998) (19)
Pain and CPX elevation after intramuscular digoxin. (1973) (19)
Absolute Bioavailability and Effect of Food and Antacid on Diazepam Absorption from a Slow‐Release Preparation (1984) (19)
Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. (1987) (19)
Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam (1997) (18)
Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen (2001) (18)
Comparative Single‐Dose Kinetics of Oxazolam, Prazepam, and Clorazepate: Three Precursors of Desmethyldiazepam (1984) (18)
CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor. (1999) (18)
UDP Glucuronosyltransferase ( UGT ) 1 A 6 Pharmacogenetics : II . Functional Impact of the Three Most Common Nonsynonymous UGT 1 A 6 Polymorphisms ( S 7 A , T 181 A , and R 184 S ) (2005) (18)
Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. (1989) (18)
Sex differences in diazepam protein binding in patients with renal insufficiency. (1978) (18)
Alprazolam kinetics in patients with renal insufficiency. (1986) (18)
Differential effects of benzodiazepine disposition by disulfiram and ethanol. (1980) (18)
Comparison of one‐ and six‐day urinary digoxin excretion in single‐dose bioavailability studies (1974) (18)
Designer Benzodiazepines: A Review of Published Data and Public Health Significance (2019) (18)
Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam (1983) (18)
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety (2018) (18)
Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites (1988) (18)
Plasma concentrations of temazepam, a 3-hydroxy benzodiazepine, determined by electron-capture gas-liquid chromatography. (1981) (18)
Drug toxicity in patients receiving digoxin and quinidine. (1983) (18)
Differential effect of central versus parenteral administration of morphine sulfate on regional concentrations of reduced glutathione in rat brain. (1997) (18)
Applications of stable isotope methods to studying the clinical pharmacology of antiepileptic drugs in newborns, infants, children, and adolescents. (1984) (18)
Diazepam impairs performance in normal elderly subjects. (1984) (18)
Comparative Protein Binding of Diazepam and Desmethyldiazepam (1980) (18)
Dietary choline intake modulates benzodiazepine receptor binding and gamma-aminobutyric acidA receptor function in mouse brain. (1989) (17)
Serum Creatine Phosphokinase Concentrations After Intramuscular Chlordiazepoxide and Its Solvent (1976) (17)
Disposition of oxazepam in relation to age, sex, and cigarette smoking (1981) (17)
Chronic morphine administration augments benzodiazepine binding and GABAA receptor function (2005) (17)
The ketoconazole legacy (2014) (17)
Fatal hypoglycaemia occurring after peritoneal dialysis. (1972) (17)
Presystemic Extraction: Mechanisms and Consequences (1993) (17)
The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach. (2018) (17)
Pharmacokinetic noninteraction of triazolam and ethanol. (1984) (17)
Imipramine and Buspirone in Patients With Panic Disorder Who Are Discontinuing Long-term Benzodiazepine Therapy (2003) (17)
Effect of Abdominal Radiation Therapy on Drug Absorption in Humans (1978) (16)
Drug transporters in psychopharmacology--are they important? (2000) (16)
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. 1978. (1978) (16)
Chlorpromazine and hyperpyrexia. A reminder that this drug affects the mechanisms which regulate body temperature. (1973) (16)
Propranolol interactions with diazepam, lorazepam, and alprazolam. (1985) (16)
Kinetics of high-dose i.v. diazepam. (1982) (16)
Benzodiazepine overdosage: Plasma concentrations and clinical outcome (2004) (16)
Kinetics of low-dose intravenous antipyrine: use of liquid chromatography. (1983) (16)
Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. (1989) (16)
Liquid chromatographic determination of chlordiazepoxide and metabolites in plasma. (1982) (16)
Impairment of hepatic drug oxidation by propoxyphene. (1982) (16)
Adverse Reactions to β-Adrenergic Receptor Blocking Drugs: A Report from the Boston Collaborative Drug Surveillance Program (2012) (16)
Book ReviewTextbook of Adverse Drug Reactions (1978) (16)
High-affinity benzodiazepine binding sites on rat peritoneal mast cells and RBL-1 cells: binding characteristics and effects on granule secretion. (1988) (16)
Evidence for Systematic Temporal Variation In 24‐Hour Urinary Creatinine Excretion (1977) (16)
Chronic treatment with Ro 15-1788 distinguishes between its benzodiazepine antagonist, agonist and inverse agonist properties (2004) (16)
Benzodiazepines: Safety and toxicity. (1975) (16)
Accidental Iron Poisoning in Childhood (1976) (16)
Tyr-MIF-1 augments benzodiazepine receptor binding in vivo (1987) (16)
Kinetic-dynamic modeling in clinical psychopharmacology. (1993) (16)
Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. (2006) (16)
The effect of age on sildenafil biotransformation in rat and mouse liver microsomes. (2003) (16)
Effect of lipophilicity on drug distribution and elimination: Influence of obesity (2021) (15)
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis (2014) (15)
Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: Relationship to plasma concentrations (2004) (15)
Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. (1988) (15)
Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. (2013) (15)
Effect of cimetidine on digoxin kinetics and creatinine clearance. (1984) (15)
Lidocaine plasma concentrations following administration of intraoral lidocaine solution. (1985) (15)
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. (2000) (15)
Bioinequivalence of a generic brand of diazepam. (1989) (15)
Overdosage with Pentobarbital and Secobarbital: Assessment of Factors Related to Outcome (1979) (15)
Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content (2012) (15)
Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients (1976) (15)
Studies With Stable Isotopes III: Pharmacokinetics of Tracer Doses of Drug (1985) (15)
In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet (2014) (15)
Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. (1990) (15)
Inotropic and Toxic Effects of a Polar Cardiac Glycoside Derivative in the Dog (1978) (15)
Correlates of outcome following acute glutethimide overdosage. (1979) (15)
Effect of a cocktail on diazepam absorption (1978) (14)
Absorption of oral and intramuscular chlordiazepoxide (1978) (14)
Spectrophotometric assay of antipyrine in plasma: a reevaluation. (1979) (14)
Absolute bioavailability of imipramine: Influence of food (2004) (14)
Antiretroviral boosting by cobicistat, a structural analog of ritonavir (2014) (14)
The reappearance of a monamine oxidase inhibitor (isocarboxazid) (1999) (14)
Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. (1987) (14)
Haloperidol determination in serum and cerebrospinal fluid using gas--liquid chromatography with nitrogen--phosphorus detection: application to pharmacokinetic studies. (1984) (14)
Lack of Effect of Influenza Vaccine on the Pharmacokinetics of Antipyrine, Alprazolam, Paracetamol (Acetaminophen) and Lorazepam (1989) (14)
Single‐Dose Kinetics of Prazepam, a Precursor of Desmethyldiazepam (1979) (14)
A randomized, double-blind trial of the interaction between cranberry juice and warfarin (2008) (14)
Effects of desmethyldiazepam on diazepam kinetics: A study of effects of a metabolite on parent drug disposition (1981) (14)
Measurement of clonazepam by electron-capture gas-liquid chromatography with application to single-dose pharmacokinetics. (1987) (14)
Meldonium (Mildronate): A Performance‐Enhancing Drug? (2016) (14)
Obesity effects on nitrazepam disposition. (1986) (14)
Chapter 11:The CYP3 Family (2008) (14)
Pharmacokinetic study of lorazepam overdosage. (1980) (14)
Disease-related Alterations in Cardiac Glycoside Disposition (1982) (14)
Propofol Clearance and Volume of Distribution Are Increased in Patients With Major Burns (2009) (14)
Antidepressant-Associated Hyponatremia in the Elderly (2016) (14)
Lidocaine determination in human plasma with application to single low-dose pharmacokinetic studies. (1982) (14)
Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium (1982) (14)
Clonazepam Pharmacokinetics: Comparison of Subcutaneous Microsphere Injection With Multiple‐Dose Oral Administration (2005) (14)
Plasma levels of trazodone: methodology and applications. (1984) (14)
Apparent active transport of MDMA is not mediated by P‐glycoprotein: a comparison with MDCK and Caco‐2 monolayers (2006) (14)
Flurazepam hydrochloride (1975) (14)
Kinetics and dynamics of single doses of oxazepam in the elderly: implications of absorption rate. (1986) (14)
Is Temazepam an Accumulating Hypnotic? (1984) (13)
Cocaine augments peripheral benzodiazepine binding in humans. (1990) (13)
Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats (2004) (13)
BEHAVIOURAL REACTIONS TO TRIAZOLAM (1979) (13)
APPLICATION OF A BENZODIAZEPINE ANTAGONIST (RD 15–1788) UNDER STEADY-STATE CONDITIONS OF MIDAZOLAM (1982) (13)
Determination of zopiclone in plasma by liquid chromatography with application to steady-state monitoring. (1986) (13)
SLOW ABSORPTION OF INTRAMUSCULAR CHLORDIAZEPOXIDE (1975) (13)
The Influence of the Menstrual Cycle on Triazolam and Indocyanine Green Pharmacokinetics (2000) (13)
Augmentation of GABAA receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons. (1990) (13)
Benzodiazepines: some aspects of their clinical pharmacology. (2008) (13)
The National Depressive and Manic Depressive Association Versus the Wimp (1986) (13)
Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. (1991) (13)
[Pharmacokinetics of midazolam in man (author's transl)]. (1981) (13)
Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. (1991) (13)
Effects of diphenhydramine on human eye movements (1995) (13)
PRAZEPAM, A PRECURSOR OF DESMETHYLDIAZEPAM (1978) (13)
Determination of atenolol in plasma by high-performance liquid chromatography with application to single-dose pharmacokinetics. (1986) (13)
Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. (1983) (13)
Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. (1996) (13)
Cocaine toxicity in cultured chicken hepatocytes: role of cytochrome P450. (1994) (13)
Assessment of methodology in single-dose studies of digoxin bioavailability. (1976) (13)
Drug interactions with methadone: Time to revise the product label (2014) (13)
Influence of Oral Contraceptive Use and Cigarette Smoking, Alone and Together, on Antipyrine Pharmacokinetics (1997) (13)
Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage (2004) (13)
Effects of benzodiazepine administration on A1 adenosine receptor binding in‐vivo and ex‐vivo (1992) (13)
Chronic benzodiazepine administration. X. Concurrent administration of the peripheral-type benzodiazepine ligand PK11195 attenuates chronic effects of lorazepam. (1992) (13)
Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results. (1978) (12)
Lorazepam Attenuates the Behavioral Effects of Dizocilpine (1999) (12)
The bioavailability of intranasal lignocaine. (1989) (12)
In Vitro Approaches to Anticipating Clinical Drug Interactions (2007) (12)
Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. (1983) (12)
A reevaluation of intravenous quinidine. (1978) (12)
Entry of lorazepam into cerebrospinal fluid [letter] (1980) (12)
Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. (1998) (12)
Interdose Elevation in Plasma Cortisol During Chronic Treatment with Alprazolam but not Lorazepam in the Elderly (2004) (12)
Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation (1979) (12)
Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Application to single-dose pharmacokinetic studies. (1983) (12)
Methadone Disposition: Implementing Lessons Learned (2019) (12)
Automated electron-capture gas chromatographic analysis of flunitrazepam in plasma. (1982) (12)
Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration (2006) (12)
More than skin deep: transdermal drug-delivery systems. (1986) (12)
Liquid chromatographic retention of β‐adrenoceptor antagonists: an index of lipid solubility 2 (1984) (12)
An introduction to clinical pharmacokinetics. (1979) (12)
Chronic Benzodiazepine Administration XI Concurrent Administration of PK11195 Attenuates Lorazepam Discontinuation Effects (1993) (12)
Differential Side Effect Profile of Triazolam Versus Flurazepam in Elderly Patients Undergoing Rehabilitation Therapy (1991) (12)
Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls (2005) (12)
In vitro inhibition of human UGT isoforms by ritonavir and cobicistat (2018) (12)
Twice may be too many: redundant publications. (1996) (12)
Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children (2004) (12)
Simultaneous determination of lidocaine and its deethylated metabolites using gas-liquid chromatography with nitrogen-phosphorus detection. (1984) (12)
Effect of Diazepam on Plasma γ-Aminobutyric Acid in Sons of Alcoholic Fathers (1996) (12)
Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects (2014) (12)
Hepatic Clearance of Drugs in Patients With Renal Insufficiency (2013) (11)
Lorazepam: A Review of its Clinical (1981) (11)
Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys (2005) (11)
Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. (1997) (11)
Evaluation of SupermixTM as an in vitro model of human liver microsomal drug metabolism (2002) (11)
Clinical Pharmacokinetics of Lorazepam. IV. Long‐Term Oral Administration (1977) (11)
Dose‐Independent Pharmacokinetics of Intravenous Lidocaine in Humans (1983) (11)
Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. (2005) (11)
Persistence of a Posaconazole‐Mediated Drug‐Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety (2018) (11)
Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline (2016) (11)
Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE ε4-negative elderly. (2011) (11)
Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. (1985) (11)
New Pharmacokinetic Methods III. Two Simple Tests for “Deep Pool Effect” (1990) (11)
Diazepam absorption (1982) (11)
Pilot pharmacokinetic study of brotizolam, a thienodiazepine hypnotic, using electron-capture gas-liquid chromatography. (1983) (11)
Human cytochromes mediating gepirone biotransformation at low substrate concentrations (2003) (11)
Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. (1983) (11)
Ketoconazole‐Associated Liver Injury in Drug‐Drug Interaction Studies in Healthy Volunteers (2016) (11)
Kinetics of oxazepam and lorazepam in two subjects with Gilbert syndrome. (1981) (10)
Large theophylline requirements due to high theophylline clearance: verification by the antipyrine test. (1986) (10)
Clinical use of the benzodiazepines. (1981) (10)
Quantitation of flurazepam and three metabolites by electron capture gas liquid chromatography. (1988) (10)
Lack of effect of sertraline on the pharmacokinetics of alprazolam. (2000) (10)
Requirement for BSF-1 in the induction of antigen-specific B cell proliferation by a thymus-dependent antigen and carrier-reactive T cell line. (1987) (10)
More on oral contraceptives, drug interactions, herbal medicines, and hormone replacement therapy. (2000) (10)
Accidental poisoning with psychotropic drugs in children. (1976) (10)
Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate (2004) (10)
Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety (2018) (10)
Ibuprofen kinetics in patients with renal insufficiency who are receiving maintenance hemodialysis. (1985) (10)
ApoE-epsilon 4 allele and susceptibility to drug-induced memory impairment in the elderly. (1998) (10)
Can you provide a table of equivalences for benzodiazepines and other marketed benzodiazepine receptor agonists? (1997) (10)
Long v short half-life benzodiazepines in the elderly???kinetics and clinical effects of diazepam and oxazepam (1983) (10)
Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program (1975) (10)
Improved high-performance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine. (1988) (10)
Effect of alprazolam on digoxin kinetics and creatinine clearance (1985) (10)
Acute barbiturate administration increases benzodiazepine receptor binding in vivo (2004) (10)
Decline in chlordiazepoxide plasma levels during fixed-dose therapy of alcohol withdrawal. (1978) (10)
Simplified approaches to the determination of antipyrine pharmacokinetic parameters. (1988) (10)
Preparation of Scientific Reports on Pharmacokinetic Drug Interaction Studies (2008) (10)
Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. (1993) (10)
Binding of diazepam and desmethyldiazepam to plasma protein: Concentration-dependence and interactions (2004) (10)
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets (2013) (10)
Ketoconazole does not impair antipyrine clearance in humans. (1986) (10)
Cognitive toxicity of drugs used in the elderly (2001) (10)
Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents (1986) (9)
Reduced Systemic Absorption of Intrabronchial Lidocaine by High‐Frequency Nebulization (1990) (9)
Antipyrine determination in human plasma by gas--liquid chromatography using nitrogen--phosphorus detection. (1981) (9)
Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine (2004) (9)
Medication dependence and anxiety (2003) (9)
Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia (1984) (9)
Diazepam pharmacokinetics after intravenous administration in alcohol withdrawal. (1983) (9)
Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses. (1978) (9)
Psychopharmacology update: New and neglected areas (1979) (9)
Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy (1983) (9)
Ibuprofen pharmacokinetics: use of liquid chromatography with radial compression separation. (1983) (9)
Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics (2010) (9)
Benzodiazepine Treatment of Specific Anxiety States (1981) (9)
Electron capture GLC analysis of the thienodiazepine clotiazepam. Preliminary pharmacokinetic studies. (1982) (9)
Long-lasting anticonvulsant effects of diazepam in different mouse strains: Correlations with brain concentrations and receptor occupancy (2004) (9)
Problems with Drug Interactions in Treating Brain Disorders (1978) (9)
The admissibility of positive EMIT results as scientific evidence: counting facts, not heads. (1985) (9)
Paracetamol absorption from a feeding jejunostomy. (1986) (9)
Correlating pharmacokinetics and pharmacodynamics of benzodiazepines: problems and assumptions. (1987) (9)
Drug-Drug Interactions, Second Edition (2008) (9)
Clinical pharmacokinetics of chlordiazepoxide. (1978) (9)
Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. (2018) (9)
Drug transporters revisited. (2001) (9)
Impairment of diazepam clearance with low-dose oral contraceptive steroid therapy (1982) (9)
Self-poisoning with over-the-counter hypnotics. (1979) (9)
A retrospective case-control study of diseases associated with oral contraceptive use. (1975) (9)
Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity. (1985) (9)
Steady‐state plasma desmethyldiazepam during long‐term clorazepate use: Effect of antacids (1982) (9)
Does zolpidem have unique clinical properties? — A Pharmacodynamic Comparison with Triazolam and Placebo (1996) (9)
Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl (2019) (9)
Cyclosporine Blood Concentrations Determined by Specific Versus Nonspecific Assay Methods (1986) (9)
Analysis of generic antiretroviral formulations manufactured in India. (2004) (9)
Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination (2017) (8)
Rational use of psychotropic drugs. I. Hypnotics. (1974) (8)
Benzodiazepine recognition site ligands: biochemistry and pharmacology. (1985) (8)
Benzodiazepine hypnotic metabolism: drug interactions and clinical implications (1986) (8)
Identification of 7-chloro-5-(2'-fluorophenyl)-2,3-dihydro-2-oxo-1H-1, 4-benzodiazepine-1-acetaldehyde, a new metabolite of flurazepam in man. (1983) (8)
Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. (1987) (8)
Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. (1984) (8)
Close correlation of acetaminophen clearance with that of conjugated benzodiazepines but not oxidized benzodiazepines (2004) (8)
HALAZEPAM, ANOTHER PRECURSOR OF DESMETHYLDIAZEPAM (1982) (8)
Disposition of intravenous diazepam in young men and women (2004) (8)
Clinical Pharmacology and Therapeuticsof Antidepressants (2011) (8)
Pharmacologic management of dental anxiety: conscious versus unconscious sedation. (2006) (8)
Pharmacotherapy of cardiopulmonary arrest. (1976) (8)
Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents. (1979) (8)
Serum digoxin concentrations and subjective manifestations of toxicity. (1980) (8)
Defining the maximum tolerated dose : An update (2000) (8)
Pharmacokinetics: Dose‐Dependent Changes (1986) (8)
Bioavailability Studies of Drugs with Nonlinear Pharmacokinetics: I. Tracer Dose AUC Varies Directly with Serum Concentration (1992) (8)
Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation (2010) (8)
Nefazodone in vitro: Metabolic conversions, and inhibition of P450‐3A isoforms (1996) (8)
Propranolol kinetics: use of automated liquid chromatography. (1984) (8)
PHARMACOKINETICS OF MIDAZOLAM IN RENAL FAILURE PATIENTS (1982) (8)
In situ hybridization histochemistry as a method to assess GABAAreceptor subunit mRNA expression following chronic alprazolam administration (1999) (8)
Pharmacokinetic determinants of the response to single doses of chlordiazepoxide. (1974) (8)
Automated high-performance liquid chromatographic analysis of tetracycline in urine. (1989) (8)
ADVERSE REACTIONS TO PROPRANOLOL IN HOSPITALIZED MEDICAL PATIENTS: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM (1974) (7)
Antipyretic analgesic drugs as models for studies of drug disposition in old age. (1983) (7)
Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance (2005) (7)
Stereo‐Psychopharmacology: The Case of Citalopram and Escitalopram (2016) (7)
Determination of ciramadol and dezocine, two new analgesics, by high-performance liquid chromatography using electrochemical detection. (1986) (7)
More on drugs and pregnancy. (1995) (7)
Acetaminophen pharmacokinetics in women receiving conjugated estrogen (2004) (7)
Antipyrine Pharmacokinetics in Women Receiving Conjugated Estrogens (1988) (7)
Absolute bioavailability of imipramine: Influence of food (2004) (7)
Ketoconazole (K) Inhibition of Intestinal and Hepatic Cytochrome P450 3A4 (CYP3A4) Activity Using Midazolam (M) As An in Vivo Probe (1999) (7)
Effect of Midazolam Infusion and Flumazenil Administration on Epinephrine Arrhythmogenicity in Dogs Anesthetized with Halothane (1993) (7)
Functional tolerance to lorazepam in the rat (2004) (7)
More on potassium, the heart, and antipsychotic agents. (1999) (7)
Effect of 7‐day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic‐pharmacodynamic relationships in individual animals (2002) (7)
Drug-drug noninteractions. (2009) (7)
Benzodiazepine receptor binding response to acute and chronic stress is increased in aging animals. (1991) (7)
Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls. (2016) (7)
Pharmacokinetics of dezocine, a new analgesic: Effect of dose and route of administration (2004) (7)
Pharmacotherapy and Psychotherapy (1982) (7)
Nifedipine: Kinetics and dynamics after single oral doses (1984) (7)
Emergency room study of sedative-hypnotic overdosage: a study of the issues (1982) (7)
Mechanism of in‐vitro inhibition of UGT1A1 by paritaprevir (2017) (7)
Drug-Drug Interactions: Clinical Perspective (2001) (7)
Disposition of clotiazepam: Influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol (2004) (7)
Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. (1977) (7)
Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin (1981) (7)
Drug Absorption Rate: A Critical Component of Bioequivalence Assessment in Psychopharmacology (1987) (7)
Cerebrospinal Fluid Digoxin Concentrations in Humans (1978) (7)
Unusually Low Clearance of Two CYP3A Substrates, Alprazolam and Trazodone, in a Volunteer Subject with Wild‐Type CYP3A4 Promoter Region (2000) (7)
The importance of presystemic extraction in clinical psychopharmacology. (1996) (7)
Selective serotonin reuptake inhibitor antidepressants: cardiovascular complications--sorting through findings. (2001) (7)
Preclinical rodent toxicity studies for long term use of ceftriaxone (2015) (7)
Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension. (1981) (7)
The psychiatrist as mind sweeper. (1982) (7)
Falling off the straight line: some hazards of correlation and regression. (1992) (7)
Antipyrine Kinetics in Patients with Primary Biliary Cirrhosis (1993) (6)
Inhibition of 2‐methoxyestradiol glucuronidation by probenecid (2015) (6)
Accelerated benzodiazepine receptor recovery after lorazepam discontinuation (1991) (6)
A BENZODIAZEPINE MOOD EFFECT SCALE: RELIABILITY AND VALIDITY DETERMINED FOR ALCOHOL-DEPENDENT SUBJECTS AND ADULTS WITH A PARENTAL HISTORY OF ALCOHOLISM (2001) (6)
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate (2010) (6)
Evaluation of the Hypothalamic—Pituitary Effects of Digoxin (1984) (6)
Oxaprozin pharmacokinetics in patients with congestive heart failure. (1986) (6)
Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs. (1985) (6)
Effect of ketanserin on the kinetics of digoxin and digitoxin. (1985) (6)
Kinetics and cardiac effects of propranolol in humans (1982) (6)
Disposition of oxazepam in patients on maintenance hemodialysis (1984) (6)
Benzodiazepine overuse-misuse. (1984) (6)
Benzodiazepine response and receptor binding after chronic ethanol ingestion in a mouse model. (1991) (6)
Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo (1990) (6)
Chronic benzodiazepine administration: effects in vivo and in vitro. (1990) (6)
Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. (1999) (6)
Clinical indications for plasma level monitoring of psychotropic drugs. (1979) (6)
Impaired Absorption of Tetracycline by Colestipol Is Not Reversed by Orange Juice (1989) (6)
Protease inhibitors and drug interactions--an alert. (1996) (6)
Overdosage with antipsychotic agents. (1980) (6)
Therapeutic Drug Monitoring of Antidepressants. (2019) (6)
Prenatal benzodiazepine administration. II. Lorazepam exposure is associated with decreases in [35S]TBPS binding but not benzodiazepine binding (1991) (6)
The Chronic Patient: Issues and Concerns???Part II (1986) (6)
Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. (1977) (6)
Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine (2004) (6)
Magnesium pemoline and iob performance in mentally handicapped workers (1969) (6)
The Impact Non-Factor. (2017) (6)
Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old (2018) (6)
Sleep and geriatric psychopharmacology (2008) (6)
An interactive model for panic disorders. (1984) (6)
Long-term Therapeutic Use of Benzodiazepines (2016) (6)
Pharmacokinetic determinants of hypnotic drug action: The art and science of controlling release (2006) (6)
Intravenous digoxin as a bioavailability standard (1975) (6)
Conflicts of interest, redundant publication, and identification of authorship: a plea for trust instead of suspicion. (1998) (6)
Chronic diazepam treatment in psychiatric outpatients. (1982) (6)
Sensitivity to Triazolam in the Elderly (1992) (6)
Benzodiazepine binding sites on PC12 cells: Modulation by nerve growth factor and forskolin (1988) (6)
The effect of chronic lorazepam administration in aging mice (2006) (6)
Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. (2019) (6)
Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype (2004) (6)
Pharmacokinetics of Psychotropic Drugs in the Elderly (1999) (6)
Pharmacokinetics and bioavailability of ciramadol, a new analgesic (1985) (5)
Drug interactions in clinical perspective (1977) (5)
Effect of diazepam on plasma gamma-aminobutyric acid in sons of alcoholic fathers. (1996) (5)
High-performance liquid chromatographic assay of adinazolam and its desmethyl metabolite. (1988) (5)
Fruit juices and pharmacology. (1997) (5)
Rational psycho-pharmacology for patients with medical diseases. (1976) (5)
Use of One Cannula for Both Blood Sampling and Drug Administration: A Potential Cause of Overestimation of Drug Concentration (1998) (5)
Determination of the in Vivo Km and Vmax of a Drug With Tracer Studies (1987) (5)
A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat (2004) (5)
Volume of distribution – Again (2014) (5)
Atropine overdose in three children. (1972) (5)
Metoprolol or Propranolol Does Not Alter the Kinetics of Procainamide (1983) (5)
Grapefruit–medication interactions (2013) (5)
Rational use of psychotropic drugs II. Antianxiety agents. (1974) (5)
Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants. (1998) (5)
Mechanism‐based inhibition of CYP2D6 by paroxetine (2003) (5)
Opportunistic Journals in the Clinical Pharmacology Space (2018) (5)
Population Pharmacokinetics of Methylphenidate (1999) (5)
Pharmacokinetic Aspects of Anxiolytic Drug Therapy (1980) (5)
Chlordiazepoxide metabolism in mice following hepatic irradiation. (1975) (5)
Differential effects of cimetidine on drug oxidation vs conjugation: Potential mode of therapy for acetaminophen hepatotoxicity (1982) (5)
The Sunshine Act (2014) (5)
Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double‐Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir) (2010) (5)
Drug Interaction Studies With CYP3A Substrates: How Much Inhibitor Pre‐exposure Is Needed? (2012) (5)
The Maturation of Clinical Pharmacology: Recognizing the Contributions of Dr. Louis Lasagna (1998) (5)
Effect of penbutolol on lidocaine kinetics. (1983) (5)
ADVERSE REACTIONS TO INTRAVENOUS DIAZEPAM: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM (1975) (5)
Digitoxin accumulation. (1982) (5)
Chlorpromazine and Hyperpyrexia (1973) (5)
Staggered Stable Isotope Administration Technique for Study of Drug Distribution (1985) (5)
Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. (1991) (5)
Nitrazepam clearance unimpaired in patients with renal insufficiency. (1992) (5)
Reduced clearance of quinidine in elderly humans. (1977) (5)
Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. (1981) (5)
Simplified gas chromatographic analysis of ethanol in blood and tissue. (1989) (5)
Pharmacokinetics and clinical drug effects in the elderly [proceedings]. (1979) (5)
Validity of a Two‐Point Acetaminophen Pharmacokinetic Study (1990) (5)
Rapid and sensitive gas chromatographic determination of estazolam. (1993) (4)
Clinical pharmacology in drug development — an update (2015) (4)
Influence of beta-blocker coadministration on the kinetics of isosorbide mononitrate and dinitrate (1986) (4)
Say "no" to drug testing. (1990) (4)
Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine (2004) (4)
Comparative Protein Binding of Diazepam and Desmethyldiazepam * (1980) (4)
Drug interactions involving psychotropic drugs. (1978) (4)
Effect of dose on bioavailability of oral digoxin (2004) (4)
Simplified gas chromatographic assay of underivatized nitrazepam in plasma. (1985) (4)
Multiple site interaction of triazolam and ketoconazole in mice: Role of P‐glycoprotein (1999) (4)
Newer antidepressants: further reflections. (1997) (4)
Mechanisms and Consequences of Drug–Drug Interactions (2010) (4)
Pharmacokinetics and CSF entry of flurazepam in dogs. (1988) (4)
Illness Care???A Finite System? (1986) (4)
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations (2021) (4)
Effect of Ginkgo on CYP2C9: In vitro and in vivo studies (2005) (4)
New Pharmacokinetic Methods: L Estimation of Mean Serum Concentration From Trough Serum Concentration (1990) (4)
Bioequivalence of Generic Drugs in Clinical Psychopharmacology (1987) (4)
Entry of lorazepam into cerebrospinal fluid. (1980) (4)
Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence. (2020) (4)
The interactions of propranolol and ketanserin (1987) (4)
Decreased EEG Sensitivity to Alprazolam in Subjects with a Parental History of Alcoholism (2000) (4)
Brain uptake of flurazepam and of N1-desalkyl flurazepam after administration of flurazepam to the cat. (1985) (4)
Effect of cirrhosis and renal failure on the kinetics of clotiazepam (2004) (4)
Comparative pharmacodynamics of intravenous alprazolam, adinazolam, desmethyladinazolam, and placebo (1996) (4)
Benzodiazepine sensitivity in panic disorder (1989) (4)
The safety of over-the-counter drugs: some reflections and unanswered questions. (2003) (4)
Herpes and clinical psychopharmacology. (1987) (4)
Sleep‐promoting medications: Weighing the hazards of use versus non‐use (2014) (4)
The Pharmacokinetization of Psychiatry (1985) (4)
Rational use of psychotropic drugs. IV. Antidepressants. (1974) (4)
Pharmacokinetics and dynamics of penbutolol in humans: Evidence for pathway-specific stereoselective clearance (1986) (4)
Arithmetic Versus Harmonic Mean Values of Elimination Half‐Life: A Study of Triazolam (1989) (4)
Influence of vitamin E supplementation on antipyring clearance in the cebus monkey (1990) (4)
Absorption of oral tetracycline in patients with Billroth-II gastrectomy (1978) (4)
14-131 Sertraline does not inhibit cytochrome P450 (CYP) 3A-mediated drug metabolism in vivo (1997) (4)
Greetings on Our 10th and a Commentary on Redundancy in Publication (1990) (4)
Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate (1986) (4)
Pharmacokinetic comparisons. (1980) (4)
Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge (1991) (4)
Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: Influence of propranolol and metoprolol (1985) (4)
Clinical implications of serum digoxin concentrations (1981) (3)
Rational use of psychotropic drugs. III. Major tranquilizers. (1974) (3)
New anxiolytics: are they really new? (1982) (3)
Activity of a partially purified human BCGF on murine assays for B-cell stimulatory factors. I. BCGF II-like activity of human BCGF. (1987) (3)
LORAZEPAM CONJUGATION UNIMPAIRED IN BURNED PATIENTS (1985) (3)
Estimation of the Elimination Half‐Life of a Drug at Any Serum Concentration When the Km and Vmax of the Drug Are Known: Calculations and Validation With Phenytoin (1987) (3)
Explaining Some Journal Requirements (2012) (3)
Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate (2004) (3)
The clinical choice of sedative-hypnotics. (1973) (3)
Benzodiazepine use and crash risk in older patients. (1998) (3)
MAOIs and hypertension. (1992) (3)
Into the Second Year (2013) (3)
Pharmacokinetic profile of SKP‐1041, a modified release formulation of zaleplon (2011) (3)
Liquid chromatographic retention of beta-adrenoceptor antagonists: an index of lipid solubility. (1984) (3)
Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment (2021) (3)
Metabolite-parent drug interaction study: Desmethyldiazepam effect on diazepam kinetics (1981) (3)
Meta‐chloro‐phenylpiperazine (mCPP): P450‐3A‐dependent formation from nefazodone and trazodone; P450‐2D6‐dependent clearance (1999) (3)
Factors influencing blood concentrations of chlordiazepoxide: A use of multiple regression analysis (1977) (3)
The archaic barbiturate hypnotics. (1975) (3)
Opioid Prescribing: What Are the Numbers? (2018) (3)
Lithium and the newborn heart. (1990) (3)
Intravenous quinidine in congestive cardiomyopathy (1981) (3)
A Randomized, Double-Blind Trial of the Interaction between Cranberry Juice and Warfarin. (2006) (3)
Psychopharmacologic Management of Anxiety in the Cardiac Patient (1971) (3)
PII‐63 (2006) (3)
Underivatized measurement of bromazepam by gas chromatography-electron-capture detection with application to single-dose pharmacokinetics. (1986) (3)
Some current treatment options for symptoms of anxiety. (1983) (3)
Ibuprofen Does Not Impair Antipyrine Clearance (1983) (3)
Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs (2002) (3)
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of SN-38 glucuronidation levels in the liver. (2006) (3)
Chronic Low‐Dose Alprazolam Augments γ‐Aminobutyric AcidA Receptor Function (1992) (3)
Clinical Pharmacology in Drug Development (2012) (3)
Ketoconazole and Liver Injury: A Five‐Year Update (2019) (3)
Pharmacodynamics of benzodiazepines after single oral doses: kinetic and physiochemical correlates. (1984) (3)
Bioavailability of digoxin: what the clinician needs to know. (1974) (3)
38 PHARMACOKINETICS , PHARMACODYNAMICS , AND DRUG DISPOSITION (2002) (3)
Effect of blood collection tubes on antidepressant concentrations. (1987) (2)
Regression and Correlation (2015) (2)
Therapeutic drug monitoring in cardiology: recognizing pitfalls and problems. (1987) (2)
Acetaminophen kinetics in obesity (1981) (2)
A soft benzodiazepine (2015) (2)
The Saint Johns Wort drug interaction An in vitro analysis of P-glycoprotein induction due to chronic exposure (2001) (2)
Pharmacokinetics of oxaprozin in women receiving conjugated estrogen (2004) (2)
International Patterns of Clinical Use and Toxicity of Digitalis Glycosides: Report From the Boston Collaborative Drug Surveillance Program (1978) (2)
Assessing and managing drug-nutrient interactions. (2002) (2)
Mechanism of dasabuvir inhibition of acetaminophen glucuronidation. (2021) (2)
Diazepam kinetics in chronic renal failure (1981) (2)
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010 (2010) (2)
Aspartame — Is there new information? (2015) (2)
KINETICS OF HIGH-DOSE INTRAVENOUS MORPHINE IN CARDIAC SURGERY PATIENTS (1977) (2)
Role of CYP3A enzymes in the biotransformation of triazolam in rat liver (2004) (2)
Editors' note: New Board of International Consulting Editors (BICE). (2013) (2)
Welcome to a New Decade and to the Year 2000 (2000) (2)
Adverse reactions to practolol in hospitalized patients (1977) (2)
Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid (2018) (2)
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old (2019) (2)
Thyroid function monitoring for lithium-treated patients. (1988) (2)
The Seventy‐Kilogram Fantasy (2013) (2)
Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly (2020) (2)
Psychopharmacology in the Elderly Person with Cardiovascular Disease (2006) (2)
Opportunistic Journals in the Clinical Pharmacology Space (2018) (2)
Handbook of Geriatric Psychopharmacology (2002) (2)
Clinical Therapeutic Conference: Pharmacokinetic Principles in Clinical Medicine (1992) (2)
Drug therapy reviews. Rational use of psychotropic drugs. I. Hypnotics. (1974) (2)
Hypnotics and sedatives (1980) (2)
Poor bioavailability of CGS 8216 in a water/tween vehicle following intraperitoneal injection (2004) (2)
Book ReviewClinical Pharmacology of Psychotherapeutic Drugs. (1979) (2)
Panel I: The ideal training program (1987) (2)
Benzodiazepine hypnotics. (1990) (2)
A New Axis II Diagnosis: TROUBLEs (1984) (2)
Clinical Pharmacokinetics: The MCQ Approach (1988) (2)
Ethanol inhibits in‐vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes (2004) (2)
Outliers--noise, nuisance, or opportunity? (1991) (2)
Optical measurement in single cells of membrane potential changes linked to T and B lymphocyte antigen receptors. (1988) (2)
Adverse effects of LSD: a current perspective. (1970) (2)
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator (2020) (2)
Short- and Long-Acting Oral Quinidine Preparations (1978) (2)
Digitalis. Clinical implications of new facts about an old drug. (1976) (2)
Pharmacotherapy of essential hypertension. (1975) (2)
The clinical use of procainamide. (1974) (2)
Authorship (2022) (2)
Introduction to Drug-Drug Interactions (2011) (2)
Insulin sensitivity in renal failure. Fatal hypoglycemia following dialysis. (1974) (2)
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware (2022) (2)
MAOIs and drug interactions--a proposal for a clearinghouse. (1985) (2)
Whither drug distribution? (1977) (2)
Antidepressants: the second harvest and DSM-III. (1981) (2)
User unfriendly drugs--fillers, additives, excipients. (1985) (2)
Bioequivalence studies in the elderly: a pilot study of two oxazepam dosage forms. (1987) (2)
Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy (2022) (2)
Clinical pharmacokinetics of some antiarrhythmic drugs. (1979) (2)
A Nonpsychopharmacologic Commentary on Schizophrenia (1986) (2)
Effect of an Herbal Extract Containing Curcumin and Piperine on Midazolam , Flurbiprofen , and Acetaminophen Pharmacokinetics in Healthy Volunteers (2012) (2)
Clinical Pharmacokinetics of Lorazepam II. Intramuscular Injection (1979) (2)
Anxiolytic drug therapy in patients with medical disease: clinical importance of pharmacokinetic drug interactions. (1984) (1)
Propranolol's psychiatric side effects. (1983) (1)
Extrapyramidal side effects of psychotropic drugs. (1969) (1)
Drug-Induced Diseases, vol 4. (1974) (1)
In memoriam: Louis Lasagna, MD 1923-2003. (2004) (1)
The Specificity of the Extraction Fluorescence Assay for Serum or Plasma Quinidine (1981) (1)
Practice Guidelines and Lithium Levels (1992) (1)
Book ReviewFundamentals of Clinical Pharmacokinetics. (1976) (1)
Adverse Drug Reaction Probability Scale (2016) (1)
Could you please review what is currently known about drug half-life and efficacy in light of recent advances in receptor theory? (1987) (1)
In Memoriam: David A. Flockhart, 1952–2015 (2016) (1)
Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients [proceedings]. (1977) (1)
Cimetidine impairs drug oxidizing capacity in the elderly (1982) (1)
PHARMACOKINETICS AND PRELIMINARY OBSERVATIONS OF THE BEHAVIORAL EFFECTS OF MIDAZOLAM IN DOGS (1991) (1)
Ritonavir impairs clearance and enhances toxicity of trazodone (2003) (1)
Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis (2010) (1)
Canny Cases???The Teaching Value of Vignettes (1994) (1)
MedWatch, the new FDA adverse effects reporting system. (1993) (1)
Introduction: pharmacokinetic considerations. Benzodiazepine hypnotics: the interface of basic and clinical science. (1991) (1)
Drug glucuronidation in obesity (1982) (1)
Short half-life benzodiazepines. (1984) (1)
American College of Clinical Pharmacology commentary on the Strategic Plan 2010–2014 Progress Report from the Office of Dietary Supplements, National Institutes of Health (2015) (1)
Mental illness, pharmacotherapy, and automobile operation: what is the risk? (1992) (1)
Obsessive-Compulsive Disorders, Transitions, a Welcome, a Thank You and Farewell (1984) (1)
Contents Vol. 63, 2001 (2001) (1)
High-Performance Liquid Chromatography: Advances and Perspectives (1982) (1)
In vitro biotransformation of phenacetin to acetaminophen: Metabolic inhibition by antidepressants (1996) (1)
Halazepam as a precursor of desmethyldiazepam: Quantitation by electron-capture gas-liquid chromatography (2004) (1)
The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor (2017) (1)
Neurotoxicity and Tretinoin (1996) (1)
A possible new approach to the treatment of neuroleptic malignant syndrome. (1992) (1)
Protein crosslinking as a therapeutic strategy for SOD1-related ALS (2021) (1)
Studies of non-linear pharmacokinetics with stable isotope labeled phenytoin (1988) (1)
Rational use of psychotropic drugs. II. Antianxiety agents. (1974) (1)
Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function. (1992) (1)
The Benzodiazepines: Kinetic-Dynamic Relationships (1993) (1)
Actual versus reported benzodiazepine usage by medical outpatients (2004) (1)
Elements of a Good Scientific Paper (2016) (1)
Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes (2018) (1)
Simplified measurement of haloperidol by gas chromatography with nitrogen-phosphorus detection. (1987) (1)
Disposition of cardiovascular drugs in the elderly. (1989) (1)
Pharmacology: Increased Cimetidine Clearance in Burn Patients (1987) (1)
Atazanavir: Effects on P-gp transport and CYP3A metabolism in vitro (2005) (1)
The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor (2017) (1)
Benzodiazepines and pregnancy--more to say and more to learn. (1989) (1)
Who Should Test the Testers?-Reply (1987) (1)
Drugs in cardiac transplantation. (1996) (1)
Regulatory and Scientific Aspects of Drug‐Drug Interaction Studies (2012) (1)
Mass units or molar units for drug concentration? (1999) (1)
It's in the bag: drug absorption by drug-delivery systems. (1997) (1)
Antipyrine kinetics in the elderly: Prediction of benzodiazepine oxidizing capacity (1981) (1)
The neurophysiological basis of social disinhibition? Lateralization of acute alprazolam induced rCBV decreases (1996) (1)
Lorazepam and oxazepam kinetics in women on lowdose oral contraceptives (1983) (1)
SAFETY OF NITRAZEPAM (1974) (1)
Metabolic, pharmacokinetic and pharmacodynamic interactions of triazolam and ketoconazole in rats (1999) (1)
Misconduct in science and misconduct against scientists. (1989) (1)
In memoriam the life of Milton Greenblatt. (1995) (1)
Baseline Plasma GABA: Its Relationship to the Adverse Effects of Acute Lorazepam Administration on Cognition in the Elderly (2004) (1)
In Memoriam: Darrell R. Abernethy, 1949–2017 (2018) (1)
Clinically unimportant pharmacokinetic drug interaction between fluvoxamine and single doses of caffeine (2005) (1)
AN AD HOC COMMITTEE FOR STUDYING STANDARDIZATION OF PHARMACOKINETIC NOMENCLATURE (1980) (1)
Editors' note: retraction notice. (2014) (1)
Alprazolam, panic disorder, and the new 2 mg tablet. (1991) (1)
COPING WITH THE PROVISIONALLY REJECTED MANUSCRIPT (1991) (1)
Benzodiazepines during early pregnancy. (1984) (1)
A Farewell, a Greeting, and a Thought about Relapses in Depression (1983) (1)
Mechanism‐based inhibition of CYP3A4 and CYP3A5 by seven inhibitors (2004) (1)
A Visit to China and a Welcome to Volume 8 and 1988 (1988) (0)
14-12 The effects of iorazepam and alprazolam on cognition in the elderly (1997) (0)
Drug therapy. Current status of benzodiazepines. (1983) (0)
Editorial manager (Ed Mr.) and not Mr. Ed (2003) (0)
Recovery of CYP3A function following single doses of grapefruit juice (2003) (0)
Yawning, a Postscript and Preliminary Thoughts about Sighing (1987) (0)
Errors in science versus scientific fraud. (1989) (0)
Effects of diazepam on performance: Relationship to dose, duration of treatment and anxiety (1989) (0)
Noninteraction of digitoxin and quinidine. (1980) (0)
537. White matter fractional anisotropy and lorazepam-induced cognitive toxicity in the elderly (2000) (0)
Drug Reactions and the Liver. Edited by Michael Davis, J . Michael Tredger, and Roger Williams. 364 pp. (including index). London: Pitman Medical Ltd., 1981. (2007) (0)
PI‐27 (2006) (0)
Technique for External Beam Treatment for Mesothelioma (1988) (0)
Differences in Diazepam and Oxazepam-Reply (1984) (0)
Desmethyldiazepam kinetics in obesity (1981) (0)
Gas chromatographic analysis of underivatized tocainide. (1987) (0)
HPLC Determination of Beta-Adrenergic Blockers in Biological Fluids (1989) (0)
Addressing the Knowledge Gaps for Providing Optimal Drug Pharmacotherapy for the Obese. (2023) (0)
Urinary-tract infection and low-dose nitrofurantoin. (1971) (0)
Recent Recall of a Generic Form of Extended-Release Paliperidone. (2017) (0)
Starting the Tenth Year (2021) (0)
Subject Index, Vol. 71, 1984 (1984) (0)
Impairment of antipyrine clearance with low-dose oral contraceptive steroid therapy (1980) (0)
Stimulation of P‐GP mediated transport & expression by flutamide in vitro (2005) (0)
Review of Medical Pharmacology (1981) (0)
Clinical Pharmacology in Drug Development: Five Years in the Books (2016) (0)
The Mitchell B. Balter Award for Research in Pharmacoepidemiology and Pharmacotherapy (1995) (0)
Cimetidine in Burned Patients-Reply (1985) (0)
Subject Index, Vol. 34, 1983 (1983) (0)
Drug Interactions with Nutrients and Natural Products (2013) (0)
with the highly significant reduction in clearance of the oxidized benzodiazepine diazepam. (1982) (0)
Identification of Human Cd8+ and Cd4+ Lymphocytes with Unique Drug Resistance Activity by Imaging the Drug Transport Kinetics at the Single Cell Resolution. (2006) (0)
Thinking while balancing: what to do about replacing dropouts. (1994) (0)
Does alprazolam produce dependency and with-drawal symptoms as do the other benzodiazepines? (1982) (0)
Medical Pharmacology: Principles and Concepts (1982) (0)
Steady-state plasma desmethyldiazepam during long-term clorazepate use: effect of antacids (1982) (0)
Pharmacotherapy of cardiopulmonary arrest. (1976) (0)
Pharmacotherapy of essential hypertension. (1975) (0)
Drs. Shader and Greenblatt Reply (1971) (0)
Academic Perspectives on the MTD: Pharmacodynamic End Points: Maximizing the Value of MTD Studies (2000) (0)
2648 – EFFECT OF INTRAVENOUS QUINIDINE ON LEFT VENTRICULAR PERFORMANCE (1978) (0)
Metabolic inhibitors of the biotransformation of mestranol to ethinylestradiol in vitro (1996) (0)
Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage (1982) (0)
In Memoriam: David A. Flockhart, 1952–2015 (2016) (0)
Liver and aging—1982: Liver & drugs. Proceedings of the Second Tokyo Symposium on Liver & Aging—Liver & Drugs, Held in Tokyo, Japan, on August 18–20, 1982. By Kenichi Kitani. 410 pp. + xiii. New York: Elsevier, 1982 (1985) (0)
Symposia—An Evolving Policy (1981) (0)
Lou Lasagna, 1923–2003 (2004) (0)
Direct Evidence that the Greater Contractility of Resistance Vessels in Spontaneously Hypertensive Rats is Associated with a Narrowed Lumen , a Thickened Media , and an Increased Number of Smooth Muscle Cell Layers (0)
Wound botulism associated with a positive Tensilon test (1985) (0)
Alprazolam and lorazepam: Differential tolerance development to the adverse memory effects in the elderly (1998) (0)
Some thoughts on a new antidepressant and a marking of the death of John Cade, MD. (1981) (0)
Pharmacodynamic Comparison of l‐Bunolol with Propranolol, Metoprolol, and Placebo (1988) (0)
"Look-alikes" and generics. (1986) (0)
Subject Index Vol. 17, 1978 (1978) (0)
Contents Vol. 71, 1984 (1984) (0)
Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In? (2019) (0)
Toward the rational use of digoxin. (1971) (0)
2837 – DOSE - INDEPENDENT PHARMACOKINETICS OF DIGOXIN IN HUMANS (1978) (0)
Letter: Safety of nitrazepam. (1974) (0)
A tribute to Dr. Hermann R. Ochs, 1943-2013. (2014) (0)
Ketoconazole differentially inhibits zolpidem and triazolam biotransformation: In vitro mechanism and in vivo consequence (1999) (0)
Mechanism of the anticonvulsant action of benzodiazepines (1990) (0)
The UGT2B15*2 polymorphism is a major determinant of oxazepam clearance in human volunteers. (2009) (0)
Drowsiness sedation levels in anxious neurotic outpatients. (1984) (0)
Back to basics--diagnosis before treatment: homelessness, hypothyroidism, aging, and lithium. (1987) (0)
Pharmacokinetics of benzodiazepine hypnotics. (1983) (0)
PharmacokineticAnalysisof Neocarzinostatinin Normal and Tumor bearing Rodents1 (2006) (0)
MANAGEMENT OF LATE-LIFE DEPRESSION (1999) (0)
Subject Index, Vol. 27 (Suppl 2), 1983 (1983) (0)
Propoxyphene inhibition of doxepin and antipyrine metabolism (1982) (0)
Editors’ Note Regarding Publication Delay (2014) (0)
Benzodiazepines: A 1990 update. Roundtable discussion (1990) (0)
Clarithromycin impairs clearance and potentiates clinical effects of trazodone but not of zolpidem (2005) (0)
In Vitro Inhibition of Human UGT Isoforms by Anti‐HIV Boosting Drugs, Ritonavir and Cobicistat (2017) (0)
Lackofinfluence ofcigarette smoking ontriazolam pharmacokinetics (1987) (0)
The substrate‐independence assumption of the relative activity factor (RAF) approach (1999) (0)
Dr. Rickels and Colleagues Reply (2002) (0)
The pharmacology of benzodiazepines: comments on terminology and sources of data (1995) (0)
Comment on the Next Chapter of the Journal of Clinical Psychopharmacology. (2020) (0)
Drugs Five Years Later (2020) (0)
428. Differential effects of alprazolam and lorazepam on plasma cortisol in normal elderly (1996) (0)
Nomifensine--a farewell and future concerns. (1986) (0)
Subject Index Vol. 63, 2001 (2001) (0)
Stability of Vancomycin and Ceftazidime With Prolonged Storage at -20°C. (2023) (0)
Editorial: Peripheral vasodilators. (1975) (0)
Dissolved hydrophobically modified alkali-soluble emulsion resins (1998) (0)
Evidence for epigenetic regulation of UGT1A1 protein expression and activity in healthy human livers (2013) (0)
Newly marketed medications: ABCs and mind your Qs. (1990) (0)
Tuberculosis is the leading cause of death in the world from a bacterial infection (2017) (0)
Phenylpropanolamine, and the Completionof Volume 2 (1982) (0)
Enhanced Propofol Clearance in Major Burns: 113. (2006) (0)
The chronic patient: issues and concerns. (1985) (0)
Urgent pharmacotherapy for drug abuse. (1975) (0)
193. Alprazolam and lorazepam: Differential effects on recall of pre-drug word lists in the elderly (1998) (0)
In Memoriam: Darrell R. Abernethy 1949–2017 (2018) (0)
The concept of geriatric clinical pharmacology. Panel I: The ideal training program. (1987) (0)
Comment: Triazolam-Cimetidine Reaction (1985) (0)
Shades of the patent medicine man. (1983) (0)
Contents, Vol. 34, 1983 (1983) (0)
Running Title: Effects of atazanavir on P-gp and CYP3A in vitro (2004) (0)
Benzodiazepine discontinuation syndromes : Clinical and experimental aspects (1996) (0)
The effect of age on triazolam hydroxylation in human liver microsomes from males (2003) (0)
Tuberculosis is the leading cause of death in the world from a bacterial infection (2017) (0)
Rational use of psychotropic drugs. IV. Antidepressants. (1974) (0)
Suggestions for treating drug abusers in a family practice. (1974) (0)
Short Communication THE EFFECT OF AGE ON SILDENAFIL BIOTRANSFORMATION IN RAT AND MOUSE LIVER MICROSOMES (2003) (0)
W-D-017 PHARMACOKINETIC PROFILE OF A MODIFIED RELEASE FORMULATION OF ZALEPLON (SKP-1041) 10.0 MG, 15.0 MG, AND 20.0 MG IN ADULTSWITH PRIMARY SLEEP MAINTENANCE INSOMNIA (2011) (0)
Strengthening the Foundation of Risk Assessment (1993) (0)
Treating the drug abuser in the ED. (1975) (0)
Is There Always a Right or Wrong?: Comments on the FDA Warnings About Triptans and the Serotonin Syndrome. (2018) (0)
Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin (2003) (0)
Lithium nephropathy and antipyretic analgesics--an uncontrolled variable. (1989) (0)
Amoxapine, an observation, and a perspective on MAOIs and their safety. (1981) (0)
A controlled trial of amantadine in drug-induced extrapyramidal disorders. (1976) (0)
Announcement (2018) (0)
Abstracts From the AAGP 12th Annual Meeting: March 14–17, 1999, New Orleans, LA: Geriatric Psychopharmacology: Enhancing Benefits, Reducing Risks: Session AbstractsPHARMACOLOGICAL INTERACTIONS (1999) (0)
The clinical use of procainamide. (1974) (0)
P3-204 Is the APOE-e4 allele associated with increased vulnerability of primacy words to retrograde interference in healthy elderly? (2006) (0)
EDITORIAL: Authorship and Coauthorship—Working out the Meaning (1987) (0)
14-13 APOE-ε 4 allele and susceptibility to benzodiazepine-induced cognitive toxicity in the elderly (1997) (0)
Anniversaries, Goodbyes, and Poisons???Life Goes On (1983) (0)
Distribution (2004) (0)
Differential modulation of CACO‐2 mediated transport of rhodamine‐123 by 17‐beta estradiol, progesterone and testosterone (2004) (0)
Designer benzodiazepines: an update (2023) (0)
413. Benzodiazepine sensitivity in panic and obsessive-compulsive disorders (1996) (0)
Pharmacogenetics in Psychiatry (1983) (0)
Drug Distribution and Pharmacologic Effect: Relation to Drug Therapy in the Elderly (1987) (0)
Abstracts of papers, * Eighty‐first Annual Meeting, March 19–21, 1980, Fairmont Hotel, San Francisco (1980) (0)
192. Alprazolam and lorazepam: Memory impairment on successive learning trials (1998) (0)
INTEGRATED PROFILING OF FURANOCOUMARINS (FC) IN GRAPEFRUIT HYBRIDS TOWARD SELECTION OF LOW FC CULTIVARS (2015) (0)
CLINICAL PHARMACOKINETICS OF LORAZEPAM 4, LONG-TERM ORAL ADMINISTRATION (1978) (0)
Effects of increasing testosterone on zolpidem clearance in vitro (2003) (0)
Drug therapy reviews: rational use of psychotropic drugs. III. Major tranquilizers. (1974) (0)
Draft legislation: the Science Research Protection Act of 1990. (1990) (0)
A single-center , phase 1 , open label , dosage-escalation study of creatine monohydrate in subject with amyotrophic lateral sclerosis (2009) (0)
Propofol clearance is altered in major burns: A-804 (2006) (0)
Pharmacokinetics of Lidocaine-Reply (1977) (0)
Can plasma levels of trazodone be measured? If so, what is the therapeutic range? (1983) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David J. Greenblatt?

David J. Greenblatt is affiliated with the following schools:

David J. Greenblatt's Academic­Influence.com Rankings

David J. Greenblatt's Degrees

Similar Degrees You Can Earn

Why Is David J. Greenblatt Influential?

David J. Greenblatt's Published Works

Published Works

What Schools Are Affiliated With David J. Greenblatt?

David J. Greenblatt's AcademicInfluence.com Rankings